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Abstract
Incorporating dual human epidermal growth factor receptor 2 (HER2) blockade into
neoadjuvant systemic therapy (NST) led to higher response in patients with
HER2-positive breast cancer. However, axillary response to treatment regimens,
including single or dual HER2 blockade, in patients with clinically node-positive
breast cancer remains uncertain. Our study aimed to examine the pathologic axillary
response according to the type of NST, that is, single or dual HER2 blockade. In our
study, 546 patients with clinically node-positive, HER2-positive breast cancer who
received NST followed by axillary surgery were retrospectively selected and divided
into three groups: chemotherapy alone, chemotherapy + trastuzumab and
chemotherapy + trastuzumab with pertuzumab. The primary outcome was the axil-
lary pathologic complete response (pCR). Among 471 patients undergoing axillary
lymph node dissection, the axillary pCR rates were 43.5%, 74.5% and 68.8% in
patients who received chemotherapy alone, chemotherapy + trastuzumab and
chemotherapy + trastuzumab with pertuzumab, respectively. There was no differ-
ence in axillary pCR rates between patients who received single or dual HER2 block-
ade (P = .379). Among patients receiving chemotherapy + trastuzumab, patients
without breast pCR had the greatest risk for residual axillary metastases (relative risk,
9.8; 95% confidence interval, 3.2-14.9; P < .0001). In conclusion, adding trastuzumab
to chemotherapy increased the axillary pCR rate in patients with clinically node-posi-
tive, HER2-positive breast cancer; furthermore, dual HER2-blockade with
trastuzumab and pertuzumab did not elevate the axillary response compared with
trastuzumab alone. Breast pCR could be a strong predictor for axillary pCR in clini-
cally node-positive patients treated with HER2-targeting therapy.
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; ALND, axillary lymph node dissection; BCS, breast-conserving surgery; ER, estrogen receptor; H, trastuzumab; HER2, human
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RR, relative risk; SLNB, sentinel lymph node biopsy; SNs, sentinel nodes; TNBC, triple-negative breast cancer.
Chihwan Cha and Sung Gwe Ahn equally contributed to this manuscript.
Received: 2 March 2021 Revised: 21 May 2021 Accepted: 21 June 2021
DOI: 10.1002/ijc.33726
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Int. J. Cancer. 2021;149:1585–1592. wileyonlinelibrary.com/journal/ijc 1585
K E YWORD S
axillary response, HER2-positive breast cancer, neoadjuvant therapy, pertuzumab,
trastuzumab
What's new?
Dual blockade of the human epidermal growth factor receptor 2 (HER2) with trastuzumab and
pertuzumab is the preferred option for neoadjuvant systemic therapy (NST) against node-posi-
tive, HER2-positive breast cancer. Whether this approach effectively improves pathologic com-
plete response (pCR), however, remains unclear. Here, comparison of pCR for single or dual
HER2 blockade shows that trastuzumab effectively increases axillary pCR rate in clinically node-
positive, HER2-positive breast cancer. The addition of pertuzumab to trastuzumab did not fur-
ther elevate pCR rate. The findings are relevant to decisions regarding axillary surgery in breast
cancer patients with pCR after NST with HER2 targeted agents.
1 | INTRODUCTION
For downstaging primary tumors, neoadjuvant systemic therapy (NST)
has been commonly used for managing patients with locally advanced
breast cancer. Moreover, robust clinical evidence suggests that
patients with pathologic complete response (pCR) after NST had a
superior survival outcome compared to those with non-pCR at an
individual level.1 Although a higher pCR rate did not automatically
suggest a better survival at the trial level, NST has been the preferred
option for managing human epidermal growth factor receptor
2 (HER2)-positive subtype or triple-negative breast cancer (TNBC).2-4
Responses to NST highly depend on tumor biology and thus differ
according to the tumor subtype. The pCR rates are higher in
HER2-positive cancer and TNBC than in other subtypes.5,6 Although
no specific target therapy is currently available for early TNBC outside
clinical trials, the development and application of HER2-targeted drugs
have improved the efficacy of NST for HER2-positive breast cancer.7,8
Specifically, incorporating dual HER2-targeted drugs into NST has led
to a higher pathologic response in patients with HER2-positive breast
cancer.9 Since dual HER2 blockade with trastuzumab and pertuzumab
has been implemented in NST, the pCR rate has increased up to
approximately 60%.10-12 Additionally, a previous prospective trial dem-
onstrated a clinical benefit of adding pertuzumab to chemotherapy and
trastuzumab as adjuvant therapy, specifically for node-positive HER2
breast cancer.13 Currently, dual HER2 blockade with trastuzumab and
pertuzumab is the preferred anti-HER2 treatment option for node-posi-
tive, HER2-positive breast cancer.14
Considering the surgeons' viewpoint, a higher response to NST
may considerably reduce the extent of axillary surgery in patients with
clinically node-positive breast cancer. Several clinical trials evaluated
the feasibility of sentinel lymph node biopsy (SLNB) after NST in
patients with initial axillary metastases.15,16 These trials commonly
suggest that SLNB could not replace axillary lymph node dis-
section (ALND) in all comers of node-positive patients at initial pre-
sentation but could be an alternative option when three or more
negative sentinel nodes (SNs) were detected and all were proven to
be negative after a pathologic evaluation.17-19 Based on these find-
ings, recent guidelines recommend SLNB instead of upfront ALND in
selected patients with conversion to node-negative disease after NST.
However, clinical reports of nodal response after neoadjuvant dual
anti-HER2 blockade remain insufficient for node-positive
HER2-breast cancer despite the addition of dual HER2-targeted ther-
apy to the armamentarium against HER2 breast cancer.
In our study, we examined the pathologic axillary response
according to the types of NST, that is, single or dual HER2 blockade, in
546 consecutive patients. Additionally, the association between axillary
pCR and breast pCR for different treatment regimens was analyzed.
2 | MATERIALS AND METHODS
2.1 | Patients
We retrospectively reviewed patients' medical records from two insti-
tutions (Gangnam Severance Hospital and Severance Hospital) from
2007 to 2018; 546 patients with clinically node-positive,
HER2-positive breast cancer treated with NST were included. All
patients had clinically axillary nodal metastasis before neoadjuvant
treatments and underwent proper axillary surgery with or without
SLNB after completing NST. Patients who discontinued chemotherapy
because of disease progression or toxicity were excluded.
HER2 status (positive or negative) was defined based on immuno-
histochemical analysis and was confirmed using fluorescence in situ
hybridization according to the American Society of Clinical Oncology/
College of American Pathologists guidelines.20 Clinical and pathologic
data of 546 patients were identified from the medical database.
Axillary nodal metastasis before chemotherapy was diagnosed by
physical examination and radiologic modalities, including ultrasonogra-
phy and magnetic resonance imaging. Among 546 patients, 376 patients
(68.9%) had pathologically proven metastatic lymph node confirmed by
fine-needle aspiration or core-needle biopsy. Details regarding neo-
adjuvant treatment regimens were collected. Patients were divided into
1586 CHA ET AL.
three groups based on whether they received single or dual
HER2-targeted therapy: chemotherapy alone, chemotherapy with
trastuzumab (H) and chemotherapy with trastuzumab and pertuzumab
(HP). Further information regarding the regimens is provided in
Table S1. Gangnam Severance Hospital Institutional Review Board
approved the study, and a waiver for obtaining informed consent was
granted based on the retrospective nature of the study.
2.2 | Axillary surgery
After completing NST, all patients underwent breast surgery (mastectomy
or breast-conserving surgery [BCS]) with proper axillary surgery (SLNB
alone, ALND after SLNB or ALND alone) (Figure S1). Before 2012, most
patients underwent upfront ALND or backup ALND after SLNB. Since
the results of the prospective studies ACOSOG-Z1071 and SENTINA
were published, ALND was omitted if at least three or more SNs were
detected and all were proven to be negative after pathologic evaluation.
SLNB was successfully performed in 361 patients. For SLN map-
ping, we preferred a radiolabeled colloid (technetium-99 m) as a single
tracer injected in peri-areolar sites.21 However, a dual tracer with blue
dye and a radiolabeled colloid were used in 36 patients (10.0%).
Lymph nodes with more than 10% of the hottest node's radioactivity
or stained with blue dye were considered SNs and resected. The type
of surgery performed was based on the surgeon's discretion.
2.3 | Pathologic evaluation
The pathologic response to NST was defined as a breast pCR if there
was no evidence of residual invasive tumor in the breast and as an axil-
lary pCR if there was no evidence of residual tumor cells in resected axil-
lary lymph nodes. Total pCR was defined as the achievement of both
breast and axillary pCRs. The pathologic status of axillary lymph nodes
was determined based on the examination of hematoxylin and eosin-
stained sections from each block of serially sectioned lymph nodes.
2.4 | Statistical analyses
The primary outcome was the axillary pCR rate of each NST regimen.
The axillary pCR rate was compared between different treatment regi-
mens and patients who underwent ALND. The secondary outcome
was the association between axillary pCR and breast pCR according
to the treatment regimen. The negative predictive value (NPV) of
breast pCR for concomitant axillary pCR was calculated for each treat-
ment regimen to assess the association between axillary pCR and
breast pCR. The incidence of pathologic nodal metastases was calcu-
lated for patients with and without breast pCR and compared using
relative risk (RR) ratios with 95% confidence intervals (CIs). As the sta-
tistical differences of axillary pCR rates according to treatment regi-
mens were similar across the cohort and in patients who underwent
ALND, NPV and RR were analyzed only for the cohort.
Data were analyzed using the Statistical Package for the Social
Sciences version 23.0. Clinicopathologic characteristics of the groups
were compared using chi-squared analysis and Mann-Whitney U test.
We used a logistic regression model to identify predictive factors for
axillary pCR. The statistical significance level (P) was taken as a mea-
sure of the strength of evidence, and P < .05 was considered statisti-
cally significant.
3 | RESULTS
3.1 | Patient characteristics
Among 546 patients in our study, 285 (52.2%) were treated with che-
motherapy alone; 134 (24.5%) with chemotherapy and trastuzumab
(H) and 127 (23.3%) with chemotherapy, trastuzumab and pertuzumab
(HP). The majority of patients (68.4%) in the chemotherapy alone
group underwent surgery in the early period (from 2007 to 2011).
Among all patients, 333 patients (61.0%) achieved axillary pCR
after NST and 261 patients (47.8%) achieved breast pCR. Moreover,
223 patients (40.8%) achieved total pCR. Patient and tumor character-
istics according to neoadjuvant treatment regimens are summarized in
Table 1. There were no differences between study groups with
respect to age, estrogen receptor (ER) status and clinical nodal stage
at diagnosis. Initial tumor size was larger in the HP subgroup than in
the other groups. The rates of BCS were not different among the
study groups, whereas the rate of ALND regardless of SLNB was
the highest in the group preoperatively treated with chemotherapy
alone (P < .001).
3.2 | Breast and axillary pCR rates according to
preoperative treatment regimen
Breast and axillary pCR rates according to treatment regimen are
shown in Figure 1. The axillary and breast pCR rates were 44.9%,
78.2% and 80.2%, and 34.7%, 53.4% and 72.2% in patients in the che-
motherapy alone group, H group and HP group, respectively
(P < .001, P < .001). The breast pCR rate was higher in the group
treated with a dual HER2 blockade than in the group treated with a
single HER2 blockade (P = .002). However, there was no difference in
the axillary pCR rates between the two groups (trastuzumab with or
without pertuzumab) (P = .778). The axillary pCR rates were higher
than the breast pCR rates for all treatment regimens, and the differ-
ence between the axillary and breast pCR rate was the greatest in the
group receiving trastuzumab (24.8%, P < .001). The addition of
trastuzumab to chemotherapy led to a higher axillary pCR rate by
1.7-fold and a higher breast pCR rate by 1.5-fold compared with che-
motherapy alone. However, the addition of pertuzumab to a
trastuzumab-containing regimen increased the breast pCR rate but
did not increase the axillary pCR rate.
A sensitivity analysis was performed in patients with biopsy-
proven axillary metastasis. As shown in Figure S2, axillary pCR rates
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were 43.2%, 76.6% and 73.3% in the chemotherapy alone group, H
group and HP group, respectively (P < .001). There was no difference
in the axillary pCR rates between the H and HP groups (P = .610);
after stratifying by clinical nodal stage, there was still no difference in
the axillary pCR rates between both the groups.
3.3 | Axillary pCR in patients undergoing ALND
Regarding axillary surgery, 361 patients (66.1%) underwent SLNB
and 471 patients (86.3%) underwent ALND. Among 471 patients
undergoing ALND, the axillary pCR rates were 43.5%, 74.5% and
TABLE 1 Clinical and pathologic characteristics
Characteristics
Study groups
Chemotherapy only (N = 285) Chemotherapy + H (N = 134) Chemotherapy + HP (N = 127) P value
Age (y), median (range) 50 (26-70) 51 (27-76) 48 (22-75) .069
ER status .071
Positive 150 (52.6) 61 (45.5) 52 (40.9)
Negative 135 (47.4) 73 (54.5) 75 (59.1)
Initial T size (cm), median (range) 3.2 (0.7-10.0) 3.5 (0.8-10.0) 3.9 (1.5-10.7) .004
Initial nodal stage .816
cN1 207 (72.6) 101 (75.4) 92 (72.4)
cN2/cN3 78 (27.4) 33 (24.6) 35 (27.6)
Clinical stage at diagnosis .580
II 179 (62.8) 80 (60.2) 73 (57.5)
III 106 (37.2) 53 (39.8) 54 (42.5)
Breast surgery .085
BCS 93 (32.6) 58 (43.6) 43 (34.1)
Total mastectomy 192 (67.4) 75 (56.4) 83 (65.9)
Axillary surgery <.001
SLNB only 7 (2.5) 21 (15.7) 47 (37.0)
ALND after SLNB 174 (61.1) 54 (40.3) 58 (45.7)
ALND only 104 (36.5) 59 (44.0) 22 (17.3)
Abbreviations: ALND, axillary lymph node dissection; BCS, breast-conserving surgery; ER, estrogen receptor; H, trastuzumab; HP, trastuzumab and




















F IGURE 1 Breast and axillary
pathologic complete response
rates according to neoadjuvant
treatment regimens. Blue, orange
and green bars indicate breast,
axillary and total pCR rates,
respectively. H, trastuzumab; HP,
trastuzumab and pertuzumab;
pCR, pathologic complete
response [Color figure can be
viewed at wileyonlinelibrary.com]
1588 CHA ET AL.
68.8% in the chemotherapy alone, H and HP groups, respectively
(P < .001). There was no difference in the axillary pCR rates
according to single or dual HER2 blockade (P = .379). Among 286
patients undergoing ALND after SLNB, 197 patients underwent
ALND despite negative SLNB results. In this subgroup, the axillary
pCR rates were 72.6%, 89.1% and 87.6% in the chemotherapy
alone, H and HP groups, respectively (P = .028). There was no dif-
ference in the axillary pCR rates according to single or dual HER2
blockade (P = .718). Among 104 patients with more than three sen-
tinel lymph nodes retrieved, the axillary pCR rates indicating the
candidates for omission of ALND were 39.4%, 75.0% and 72.7% in
the chemotherapy alone, H group and HP group, respectively
(P = .003). There was no difference in the axillary pCR rates
according to single or dual HER2 blockade (P = .875).
3.4 | Predictors of axillary pCR
According to a univariate analysis, clinical N1 stage at diagnosis,
chemotherapy with H or HP, breast pCR and ER negativity were
found to be significant predictors of axillary pCR. Moreover,
according to a multivariate logistic regression analysis, breast pCR
was the most significant predictor for axillary pCR (odds ratio [OR],
7.187; 95% CI, 4.586-11.264; P < .001). Additionally, chemother-
apy with H (OR, 4.164; 95% CI, 2.457-7.058; P < .001), chemother-
apy with HP (OR, 3.172; 95% CI, 1.788-5.628; P < .001), clinical N1
stage at diagnosis (OR, 1.755; 95% CI, 1.089-2.826; P = .021) and
ER negativity (OR, 1.652; 95% CI, 1.080-2.526; P = .021) were
significant predictors for axillary pCR after adjusting age and tumor
size (Table 2).
3.5 | Association between breast and axillary pCR
according to treatment regimens
Among 285 patients receiving chemotherapy alone, 28 had breast pCR
only and 71 had total pCR (both breast and axillary pCRs, Table S2). The
NPV of breast pCR for concomitant axillary pCR was 71.7% (71/[71
+ 28]  100). Among 134 patients receiving chemotherapy with H, three
had breast pCR only and 68 had total pCR. The NPV of breast pCR for axil-
lary pCR was 95.8% (68/[68 + 3]  100). Among 127 patients receiving
chemotherapy with HP, seven had breast pCR only and 84 had total pCR.
The NPV of breast pCR for axillary pCR was 92.3% (84/[84 + 7]  100).
The NPV was significantly higher in the H group than in the chemotherapy
alone group (P < .0001); however, there was no difference between the
single and dual HER2 blockade groups (P = .374) (Figure 2). False-negative
rates for predicting axillary pCR with breast pCR were 17.7%, 10.3% and
26.9% in the chemotherapy alone, H and HP groups, respectively.
Table 3 shows the RR ratios comparing the incidence of residual
axillary nodal metastases after NST between patients with and with-
out breast pCR. Patients receiving chemotherapy with H had the
greatest increase in RR for residual axillary metastases among patients
without breast pCR (RR, 9.8; 95% CI, 3.1-30.7; P < .0001). RRs for
residual axillary metastases were 2.5 (95% CI, 1.8-3.4; P < .0001), and
6.9 (95% CI, 3.2-14.9; P < .0001) in patients receiving chemotherapy
alone and chemotherapy with HP, respectively.
TABLE 2 Univariate and multivariate
analyses to determine predictors of
axillary pathologic complete response Variables
Univariate analysis Multivariate analysis
OR (95% CI) P value OR (95% CI) P value
Age (y)a 1.017 (0.998-1.036) .079 — —
Initial tumor size (cm)a 0.970 (0.891-1.055) .474 — —
Initial nodal stage .008 .021
Clinical N2/N3 stage Reference Reference
Clinical N1 stage 1.608 (1.131-2.286) 1.755 (1.089–2.826)
Treatments
Chemotherapy Reference Reference
Chemotherapy with H 2.498 (1.948-3.204) <.001 4.164 (2.457–7.058) <.001
Chemotherapy with HP 3.131 (1.953-5.020) <.001 3.172 (1.788–5.628) <.001
Breast pCR <.001 <.001
Non-pCR Reference Reference
pCR 9.368 (6.161-14.245) 7.187 (4.586–11.264)
Estrogen receptor <.001 .021
Positive Reference Reference
Negative 2.139 (1.507-3.036) 1.652 (1.080–2.526)
Abbreviations: CI, confidence interval; H, trastuzumab; HP, trastuzumab and pertuzumab; OR, odds ratio;
pCR, pathologic complete response.
aAge and initial tumor size were considered continuous variables.
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4 | DISCUSSION
Dual HER2 blockade with trastuzumab and pertuzumab has become
the most preferred therapeutic option for patients with node-positive,
HER2-positive breast cancer, with clinical trials demonstrating its
superiority to single HER2 blockade in terms of pCR rate9,10 and
disease-free survival.13 If the addition of pertuzumab to NST with
trastuzumab increases the axillary pCR rate and subsequently
increases the total breast and axillary pCR rates, dual HER2 blockade
may further reduce the frequency of axillary surgery for patients with
clinically node-positive, HER2-positive breast cancer. Thus, we
wanted to determine whether dual HER2 blockade has more advan-
tages than single HER2 blockade with regard to pathologic axillary
response in node-positive breast cancer. According to our results, we
found that the axillary pCR rate was higher in patients with node-posi-
tive, HER2-positive breast cancer who received NST with
trastuzumab and chemotherapy than in those who received NST
with chemotherapy alone. However, dual HER2 blockade with
trastuzumab and pertuzumab did not increase the axillary pCR rate.
Correspondingly, it is inferred that increased total pCR rate by dual
HER2 blockade might be mainly attributed to the improvement of
breast pCR and not to that of axillary pCR, although breast pCR was
recognized as a strong predictor for axillary pCR (Table 2).
Currently, few studies have compared axillary pCR directly
between patients who received NST with or without trastuzumab.
Our findings suggest that treatment with trastuzumab and chemo-
therapy improves the axillary pCR rate compared with treatment with
chemotherapy alone in patients with clinically node-positive breast
cancer. The higher axillary response in patients receiving trastuzumab
might be explained by the immune system activation associated with
antibody-dependent cellular cytotoxicity (ADCC).22 The activation of
ADCC has been described as an important mechanism of action
of trastuzumab.23-25 As the immune system activation would be sig-
nificantly effective in the lymphoid tissue of metastatic axillary nodes,
NST with trastuzumab could enhance the axillary response in patients
with metastatic lymph nodes. The axillary pCR rate of 78.2% in the
chemotherapy with trastuzumab group in our study is consistent with
the rate reported in a previous study. According to Dominici et al's
study of 109 patients with HER2-positive breast cancer and axillary
metastasis,26 the axillary pCR rate was 74% in patients receiving che-
motherapy with trastuzumab, suggesting that our axillary pCR rate
corresponding to single HER2 blockade is reliable.
The axillary pCR rate of dual HER2 blockade has not been widely
studied in patients with node-positive and HER2-positive breast can-
cer. In the current study, dual HER2 blockade comprising pertuzumab
and trastuzumab did not lead to higher axillary pCR rates compared
with single HER2 blockade with trastuzumab alone. The multivariate
analysis revealed that the OR of dual HER2 blockade was 3.172
(1.788-5.628), which was numerically lower than that of single HER2
blockade (4.164 [2.457-7.058]) for axillary pCR, supporting the
(A) Among the three subgroups according


















P < .0001 P = .374
P = .0003
(B) Between the two subgroups according















F IGURE 2 Positive predictive value of breast pathologic complete
response (pCR) for concomitant axillary pCR according to treatment
regimens. A, Among the three subgroups according to different
treatment regimens. B, Between the two subgroups according to the
use of trastuzumab. H, trastuzumab; HP, trastuzumab and
pertuzumab [Color figure can be viewed at wileyonlinelibrary.com]
TABLE 3 Relative risks for residual axillary metastases after NST
in patients without and with breast pCR according to treatment
regimens
Treatment regimen RR (95% CI) P value
Chemotherapy alone 2.5 (1.8-3.4) <.0001
Chemotherapy with H 9.8 (3.1-30.7) <.0001
Chemotherapy with HP 6.9 (3.2-14.9) <.0001
Abbreviations: CI, confidence interval; H, trastuzumab; HP, trastuzumab
and pertuzumab; NST, neoadjuvant systemic therapy; pCR, pathologic
complete response; RR, relative risk.
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hypothesis that the addition of pertuzumab did not increase nodal
response. Additionally, it is noteworthy to emphasize that the differ-
ence between the axillary and breast pCR rates was significantly
observed in the single HER blockade group (Figure 2). Taken together,
the synergistic effect of pertuzumab with trastuzumab might be con-
fined to increased breast pCR. This finding might be explained by the
nonsynergistic effect of dual HER2 blockade on ADCC activation.
The combination of trastuzumab and pertuzumab at receptor-
saturating concentrations did not enhance ADCC activity based on an
in vitro analysis.27 It could be assumed that HER2-binding saturation
with trastuzumab might be sufficient to activate the maximum
response of immune effector cells in vivo; hence, there was no differ-
ence between the axillary pCR rates of single and dual HER2 block-
ade. Further studies are needed to corroborate our findings.
Regarding the associations between breast pCR and axillary pCR,
several studies have reported that breast pCR is highly predictive of
axillary pCR, as in our study. Tadros et al reported that breast pCR
was highly associated with axillary pCR after NST.28 In this cohort
study of 527 consecutive patients with HER2-positive or triple-
negative (T1/T2 and N0/N1) breast cancer who achieved breast pCR
after NST, 185 of the 193 (95.9%) patients achieved axillary pCR.
They suggested that the feasibility for the omission of axillary surgery
could be assessed in highly selective patients with breast pCR in a
future prospective trial. In our results, patients with initial clinical node
metastasis receiving chemotherapy with trastuzumab had a higher
NPV of breast pCR (95.8%) for concomitant axillary pCR than patients
receiving chemotherapy alone. However, the addition of pertuzumab
did not increase the NPV of breast pCR compared with single HER2
blockade. Moreover, the RR for residual axillary metastases after NST
in patients without breast pCR was greater among patients receiving
single HER2 blockade than among those receiving dual HER2 block-
ade. To our knowledge, this is the first study investigating the associa-
tion between breast and axillary pCR according to NST regimen
containing single or dual HER2 blockade agents.
The potential limitation of our study is its retrospective study
design. To compare the axillary response between the chemotherapy
only treatment regimen and single or dual HER2 blockade, our study
included patients who underwent NST from 2007 to 2018; the
expanded study period could result in a potential selection bias. Most
patients in the chemotherapy only group were treated at the begin-
ning of the study period, while patients with single or dual HER2
blockade were treated mostly at the end. Since two prospective trials
evaluating the role of SLNB in node-positive patients were announced
in 2012,15,16 the rate of ALND might be affected by the study period.
Furthermore, the implications of these findings on surgical decisions
might vary among institutions and individual surgeons; therefore, our
end point was axillary pCR rather than the type of axillary surgery.
Despite this limitation, most patients (86.3%) in our study underwent
ALND, and all surgically resected nodes were evaluated.
Another limitation is that backbone chemotherapy regimens
and the frequency of delivered HER2 targeting therapy were dif-
ferent between single- and dual-HER2 blockade groups
(Table S1). Sequential anthracylines and taxanes were used only
in the single-HER2 blockade group. In addition, fourth cycles of
trastuzumab were delivered in the single HER2 blockade group
and sixth cycles of HP were done in the dual group. Different fre-
quencies and regimens of chemotherapy and HER2 targeted ther-
apy could influence nodal pCR outcome. However, we primarily
aimed to know axillary response according to the types of HER2
blockades which are most preferred in daily practice, this limita-
tion raised by different backbone chemotherapy regimen could
be acceptable.
Further studies are required to confirm the reproducibility of our
findings in patients with clinically node-positive, HER2-positive breast
cancer treated with NST. Currently, there is an ongoing prospective,
multicenter, single-arm trial (NCT 04101851) investigating the feasi-
bility of omitting axillary surgery in triple-negative or HER2-positive
patients with radiologic CR and confirmed breast pCR on lumpectomy
after NST.29 This study is based on the same rationale shown in our
findings, namely that in-breast pCR is the best predictor for axillary
nodal pCR.
In conclusion, adding trastuzumab to chemotherapy increased the
axillary pCR rate in patients with clinically node-positive,
HER2-positive breast cancer, whereas dual HER2-blockade with
trastuzumab and pertuzumab did not elevate the axillary response
compared with trastuzumab alone. The association between breast
pCR and axillary pCR was stronger in patients receiving trastuzumab
than in those receiving chemotherapy alone. Our findings could be
implicated in the future clinical trials which evaluate the oncologic
safety of de-escalating axillary surgery in patients with breast pCR
after NST with HER2 targeted agents.
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